A Multicenter Study of Pulsed Field Ablation for Paroxysmal Supraventricular Tachycardia (PSVT)

Inclusion Criteria: 18 years old ≤ age ≤ 80 years old, regardless of gender Patients with symptomatic paroxysmal supraventricular tachycardia PSVT (AVNRT or AVRT) documented by ECG, Holter or electrophysiological examination Recurrent episodes of disease prior to enrollment Fully understand the treatment protocol and voluntarily sign an informed consent form, willing to undergo the tests, procedures and follow-ups required by the protocol Exclusion Criteria: Previous failure or recurrence of radiofrequency ablation Left ventricular ejection fraction (LVEF) ≤ 40% Combined with atrial flutter or atrial fibrillation Combination of thromboembolic disease Women who are breastfeeding, pregnant or planning to become pregnant during the study period Carrying active implants in the body (e.g., pacemakers, ICDs, etc.) Patients with second-degree (type II) or third-degree atrioventricular block NYHA Class III-IV cardiac function [Appendix 1] Patients with congenital heart disease (excluding atrial septal defect and patent foramen ovale) Patients with definite acute cerebrovascular disease (including cerebral hemorrhage, stroke, transient ischemic attack) within the last 1 month cardiovascular events within the last 3 months (including acute myocardial infarction, coronary intervention or heart bypass surgery, prosthetic valve replacement or repair, atrial or ventriculotomy) Acute or severe systemic infection Patients with severe liver and kidney diseases, malignant tumors and end-stage diseases Patients with significant bleeding tendency, hypercoagulable state and serious hematologic disorders Patients who have participated or are participating in other clinical trials within 3 months before enrollment Patients who have other conditions that the investigator considers inappropriate for participation in this trial.